Search

Displaying results 3451 - 3460 of 5449 in total
  1. Drug

    Aluminum zirconium trichlorohydrex gly

    go.drugbank.com/drugs/DB11116
    ApprovedWithdrawn

    It is consisted of a mixture of monomeric and polymeric Zr4+ and Al3+ complexes with hydroxide, chloride and glycine.

  2. Drug

    Delgocitinib

    go.drugbank.com/drugs/DB16133
    ApprovedInvestigational

    [L51913] It works to reduce the inflammatory response in inflammatory skin disorders.[A264703] On July 23, 2025, delgocitinib was also granted approval by the FDA.[L53508]

  3. Drug

    Indium In-111 chloride

    go.drugbank.com/drugs/DB09490
    Approved

    It is supplied as a sterile, pyrogen-free solution of Indium ("'In) Chloride in O.04M HCI.

  4. Drug

    Lunacalcipol

    go.drugbank.com/drugs/DB05024
    Investigational

    Cytochroma anticipates that CTA018 will be more potent than currently marketed vitamin D analogues such as calcitriol and calcipotriol and it is expected to have a greater safety index.

  5. Drug

    Atl146e

    go.drugbank.com/drugs/DB05191
    Investigational

    ATL146e is an anti-inflammatory compounds which is an agonist of A2A adenosine receptors.

  6. Drug

    Antilymphocyte immunoglobulin (horse)

    go.drugbank.com/drugs/DB09312
    ApprovedInvestigational

    cells, etc.). … Induction of T cell apoptosis and resulting T-cell lymphopenia found in vivo is credited for its therapeutic effect in these conditions.

    Synonyms: e-ATGCategories: Increased T Lymphocyte Destruction
  7. Drug

    Zosuquidar

    go.drugbank.com/drugs/DB06191
    Investigational

    It is now in "Phase 3" of clinical tests in the United States. Its action mechanism consists of the inhibition of P-glycoproteins; other drugs with this mechanism include tariquidar and laniquidar.

  8. Drug

    EP-1043

    go.drugbank.com/drugs/DB06118
    Experimental

    EP-1043 is an epitope-based recombinant protein vaccine designed to induce HIV-1 specific helper T-lymphocyte (HTL) responses.

  9. Drug

    Taberminogene vadenovec

    go.drugbank.com/drugs/DB05011
    Experimental

    EG004 has completed a Phase II trial, this being the first part of the Phase II/III study for which it has received approval from the US Recombinant DNA Advisory Committee (RAC).

  10. Drug

    Butoconazole

    go.drugbank.com/drugs/DB00639
    Approved

    Butoconazole is an imidazole antifungal used in gynecology.